---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021169"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T10:35:03.653257+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M

## Summary
- Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.
- Full year 2023 net loss $61.3M ($0.37 loss) vs net loss $216.0M ($1.34 loss) in 2022.
- 2023 total net product sales $726.4M (+40% YoY); DAYBUE $177.2M, NUPLAZID $549.2M (+6%).
- FY2024 guidance: DAYBUE net sales $370-420M; NUPLAZID $560-590M; R&D $305-325M; SG&A $455-480M.
- Phase 3 ADVANCE-2 (pimavanserin for negative schizophrenia) top-line results due by end of Q1 2024.

## SEC filing metadata
- accession: 0000950170-24-021169
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/0000950170-24-021169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/acad-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021169
- JSON: https://secwatch.observer/filing/0000950170-24-021169.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021169.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC updated its Full Year 2024 guidance (initiated).
  - Period: Full Year 2024
  - Guidance: initiated
  - Result: guidance update
  source text: Full Year 2024 Financial Guidance • DAYBUE net product sales in the range of $370 to $420 million. • NUPLAZID net product sales in the range of $560 to $590 million. • GAAP R&D expense in the range of $305 to $325 million. • GAAP SG&A expense in the range of $455 to $480 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/0000950170-24-021169-index.htm
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported fourth quarter and full year ended December 31, 2023 results: revenue $231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023, net income net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023, EPS $0.28 per common share for the fourth quarter and $(0.37) per common share for the full year.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: $231.0 million for the fourth quarter of 2023 and $726.4 million for the full year 2023
  - Net income: net income of $45.8 million for the fourth quarter of 2023 and net loss of $61.3 million for the full year 2023
  - EPS: $0.28 per common share for the fourth quarter and $(0.37) per common share for the full year
  - Result: reported results
  source text: Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000095017024021169/0000950170-24-021169-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.